What is the mechanism of action of psilocybin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Mechanism of Action of Psilocybin

Psilocybin is metabolized to psilocin, which acts primarily as a partial agonist at serotonin 2A (5-HT2A) receptors, with additional activity at 5-HT2C and 5-HT1A receptors, triggering alterations in perception, cognition, and emotion through modulation of limbic-prefrontal circuits and enhancement of synaptic plasticity. 1

Primary Serotonergic Mechanism

The core pharmacological action involves:

  • Metabolism: Psilocybin is rapidly converted in the body to psilocin, the active metabolite 1
  • 5-HT2A receptor agonism: Psilocin functions as a partial agonist at 5-HT2A receptors, which are predominantly located in cortical regions 1, 2, 3
  • Receptor affinity profile: Psilocin demonstrates similar binding affinities across multiple serotonin receptor subtypes:
    • 5-HT2A receptors (Ki: 120-173 nM)
    • 5-HT2C receptors (Ki: 79-311 nM)
    • 5-HT1A receptors (Ki: 152-146 nM) 4

Neuroplasticity and Endocannabinoid System Modulation

Beyond direct serotonergic effects, psilocybin promotes neuroplasticity and modulates the endocannabinoid system (ECS), which may contribute substantially to its therapeutic effects 1:

  • CB1 receptor upregulation: Low-dose psilocybin increases CB1 receptor expression in mood-related brain regions including the prefrontal cortex, amygdala, hippocampus, and hypothalamus 1
  • 2-AG normalization: Attenuates stress-induced increases in 2-arachidonoylglycerol (2-AG) levels in the hypothalamus and hippocampus 1
  • Behavioral effects: These ECS changes correlate with mitigation of behavioral despair and cognitive deficits in preclinical stress models 1

Important caveat: Whether ECS modulation results from direct psilocybin action or occurs indirectly via alterations in HPA axis activity remains unclear 1

Additional Receptor Interactions

Psilocybin's mechanism extends beyond 5-HT2A receptors 3:

  • 5-HT1A receptors: Contribute to anxiolytic-like effects and thermoregulatory responses 4, 5
  • 5-HT2C receptors: Modulate the intensity of psychedelic effects; antagonism of 5-HT2C increases head-twitch response (a proxy for psychedelic intensity) 4
  • Neurotrophin receptors: Interactions with tropomyosin receptor kinase B (TrkB) may contribute to neuroplastic effects 3

Neurobiological Effects

The downstream consequences of receptor activation include:

  • Network modulation: Alterations in large-scale brain network connectivity, particularly affecting limbic-prefrontal circuits 2, 6
  • Synaptic plasticity: Enhanced formation of new neural connections and rewiring of neuronal networks 2, 3
  • Cognitive flexibility: Increased emotional and cognitive flexibility, particularly when combined with psychotherapeutic support 2
  • Anti-inflammatory effects: Regulation of immune responses via microglial activity and suppression of pro-inflammatory cytokines 6

Clinical Implications

The therapeutic effects observed in clinical trials—including rapid reductions in depressive symptoms and sustained benefits—likely result from the convergence of serotonergic receptor activation, neuroplastic changes, and ECS modulation 1, 2. The 2025 endocannabinoid guideline emphasizes that psilocybin's effects on the ECS may represent a unifying mechanism through which diverse non-monoaminergic interventions exert antidepressant effects in treatment-resistant depression 1.

Critical consideration: The 2022 U.S. Department of Veterans Affairs guideline recommends against psilocybin use outside clinical trials due to limited evidence, small sample sizes, risks of psychotic events, and potential for harmful behaviors without appropriate guidance 7. The evidence base remains experimental despite promising mechanistic data.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.